The future of biomedical research in Spain meets in Vigo

The First CIBER Young Scientific Personnel Conference has focused the debate on the future of biomedical research in Spain. Thus, it has managed to bring together 350 members from its 13 thematic research areas in Vigo. The first day had the inspiring presence…

The I CIBER Young Scientific Personnel Conference has focused the debate on andhe future of biomedical research in Spain. Thus, he has managed to bring together in Vigo 350 members from its 13 areas research topics. The first day had the inspiring presence of Federico Martinón, group leader of the CIBER Respiratory Diseases area (CIBERES) at CHUS, who gave them the recipe for success: “The key to doing competitive and useful clinical research is to generate good results.” ideas, having a multidisciplinary team and being aware that resources end up reaching good ideas.” Martinón presented the first results of the Sensogenomics project, which studies the therapeutic effects of music, “identifying the genes that are stimulated by music and how it does so differently in patients with senile dementia.” Next, the event presented CIBER and its history with the help of its manager, Margarita Blázquez, and the scientific deputy director of the area of ​​Epidemiology and Public Health (CIBERESP), Jordi Alonso. The Center is key to the Spanish Science and Innovation system and the largest biomedical research center, which brings together 508 research groups in 104 consortium institutions and organized in 13 research areaswith a staff of more than 800 hired people and more than 5,000 assigned researchers.

Future of biomedical research

The importance of collaborative research projects facilitated by this network research structure They were also the subject of a debate session on the future of biomedical research. Thus, different experiences of projects that emerged thanks to the synergies fostered by CIBER were analyzed. Among them, the ALEVINT platform was presented, which is a comprehensive tool for collecting, analyzing and nutritional assessment of diet questionnaires developed between the areas of the CIBER of Public Health (CIBERESP) and of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), presented by Emma Ruiz from CIBERESP. For their part, Regina Rodrigo, from the Rare Diseases area (CIBERER) and Idoia Gallego from CIBER-BBN, presented their project on lipid nanoparticles of the Adalimumab monoclonal antibody for ophthalmic administration. Likewise, Rodrigo Medina, Nicolás Fernández and Beatriz Morte presented the Predictive and Genomics Medicine programs of the IMPaCT Infrastructure, the reference scientific infrastructure for the development of Precision Medicine in Spain, which is coordinated and financed by the Carlos III Health Institute.